TP53 and myelodysplastic syndrome: TP53 mutations underly the aggressiveness of AML and, even though in MDS multihit TP53 mutations are required for diagnosis of MDS with mutated TP53, in AML and MDS/AML with mutated TP53, any pathogenic TP53 mutation VAF of ≥ 10% is sufficient for diagnosis [24].